HomeCompareNYMTI vs ABBV

NYMTI vs ABBV: Dividend Comparison 2026

NYMTI yields 6.80% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NYMTI wins by $695.3K in total portfolio value
10 years
NYMTI
NYMTI
● Live price
6.80%
Share price
$25.15
Annual div
$1.71
5Y div CAGR
44.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$797.6K
Annual income
$457,381.08
Full NYMTI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NYMTI vs ABBV

📍 NYMTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNYMTIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NYMTI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NYMTI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NYMTI
Annual income on $10K today (after 15% tax)
$578.25/yr
After 10yr DRIP, annual income (after tax)
$388,773.92/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NYMTI beats the other by $367,717.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NYMTI + ABBV for your $10,000?

NYMTI: 50%ABBV: 50%
100% ABBV50/50100% NYMTI
Portfolio after 10yr
$450.0K
Annual income
$241,076.42/yr
Blended yield
53.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NYMTI
No analyst data
Altman Z
0.8
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NYMTI buys
0
ABBV buys
0
No recent congressional trades found for NYMTI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNYMTIABBV
Forward yield6.80%3.06%
Annual dividend / share$1.71$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR44.2%40.6%
Portfolio after 10y$797.6K$102.3K
Annual income after 10y$457,381.08$24,771.77
Total dividends collected$738.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NYMTI vs ABBV ($10,000, DRIP)

YearNYMTI PortfolioNYMTI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,681$980.98$11,550$430.00+$131.00NYMTI
2$14,043$1,544.27$13,472$627.96+$571.00NYMTI
3$17,528$2,501.97$15,906$926.08+$1.6KNYMTI
4$22,963$4,208.58$19,071$1,382.55+$3.9KNYMTI
5$32,001$7,430.60$23,302$2,095.81+$8.7KNYMTI
6$48,197$13,955.27$29,150$3,237.93+$19.0KNYMTI
7$79,896$28,324.91$37,536$5,121.41+$42.4KNYMTI
8$148,766$63,278.19$50,079$8,338.38+$98.7KNYMTI
9$317,968$158,788.10$69,753$14,065.80+$248.2KNYMTI
10$797,607$457,381.08$102,337$24,771.77+$695.3KNYMTI

NYMTI vs ABBV: Complete Analysis 2026

NYMTIStock

New York Mortgage Trust, Inc. acquires, invests in, finances, and manages mortgage-related single-family and multi-family residential assets in the United States. Its targeted investments include residential loans, including business purpose loans; structured multi-family property investments, such as preferred equity in, and mezzanine loans to owners of multi-family properties; non-agency residential mortgage-backed securities (RMBS); agency RMBS; commercial mortgage-backed securities (CMBS); single-family rental properties; and other mortgage, residential housing, and credit-related assets. The company also qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. New York Mortgage Trust, Inc. was incorporated in 2003 and is headquartered in New York, New York.

Full NYMTI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NYMTI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NYMTI vs SCHDNYMTI vs JEPINYMTI vs ONYMTI vs KONYMTI vs MAINNYMTI vs JNJNYMTI vs MRKNYMTI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.